Cerevel Therapeutics Holdings, Inc. (CERE)
收市後：
Cerevel Therapeutics Holdings, Inc.
222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com
版塊: Healthcare
行業: Biotechnology
全職員工: 355
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. N. Anthony Coles Jr., M.P.H. | Executive Chairman | 729.77k | 13.53M | 1960 |
| Mr. Ronald C. Renaud Jr., M.B.A. | President, CEO & Director | 1.03M | 無 | 1969 |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer | 633.06k | 無 | 1982 |
| Mr. Mark Bodenrader | Senior VP of Finance & Chief Accounting Officer | 508.39k | 無 | 1973 |
| Dr. John J. Renger Ph.D. | Chief Scientific Officer | 689.25k | 無 | 1969 |
| Dr. Ramiro Sanchez M.D. | Chief Medical Officer | 711.57k | 1M | 1961 |
| Mr. Paul D. Burgess J.D. | Chief Business Development & Strategic Operations Officer | 545.72k | 無 | 1974 |
| Mr. Matthew Calistri | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Scott M. Akamine J.D. | Chief Legal Officer & Corporate Secretary | 444.74k | 無 | 1985 |
| Mr. Kenneth A. DiPietro | Chief Human Resources Officer | 無 | 無 | 1959 |
描述
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年5月1日 止，Cerevel Therapeutics Holdings, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：7；股東權利：5；現金賠償：6。
